In part 3 of this Exclusive Interview, Dr. Rhinehart shares his thoughts with DIC publisher Steve Freed on the benefits of SGLT-2 and GLP-1s. What do these new medications offer when it comes to costs, side effects and staying on top of the research to help facilitate use in the right patients?
Andy Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC, is the Chief Medical Officer at Glytec Systems, a clinical information technology company dedicated to the mission of improving insulin management and glycemic control. Dr. Rhinehart previously served as a diabetologist and the program director of the Johnston Memorial Diabetes Care Center and Johnston Memorial Center for Comprehensive Wound Care in Abingdon, Va. He was also the chairman of the ADA’s Primary Care Advisory Group and the first physician to be Board Certified in Advanced Diabetes Management (BC-ADM) by the American Association of Diabetes Educators.